Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.

Carla DamaschinHelen GoergenStefanie KreisslAnnette PlütschowFrank BreywischStephan MathasJulia MeissnerMartin SöklerMax S ToppVladan VucinicAndreas ZimmermannBastian von TresckowMichael FuchsAndreas EngertPeter BorchmannDennis A Eichenauer

Published in: Leukemia (2021)

Keyphrases

hodgkin lymphoma
phase ii study
newly diagnosed
open label
locally advanced
copy number
randomized controlled trial
clinical trial
squamous cell carcinoma
rectal cancer
placebo controlled
study protocol